Siemens Healthineers: Buyback Momentum Meets a Margin Puzzle Ahead of the Siemens Split Vote

Siemens Healthineers' €230M buyback cushions shares, but mixed Q3 guidance and weak Diagnostics cap gains; stock still down 11% YTD.

The steady hand of Siemens Healthineers' share repurchase program is doing what it was designed to do: putting a floor under a stock that has spent most of 2026 in negative territory. Between June 1 and August 16, the medical technology group bought back 2,824,371 of its own shares, with the most recent weekly tranche — 50,000 shares acquired between August 10 and 16 — keeping the buyback on its planned trajectory. The program, sized at up to €230 million, is scheduled to run until January 29, 2027.

The market has taken notice. Shares rose 1.1 percent on Wednesday to €39.98, building on a 1.8 percent gain the prior session that left the stock at €39.55. Over the past month, the equity has climbed roughly 13 to 14 percent, and it now trades about 1.1 percent above its 200-day moving average. Yet the rebound only partially repairs the damage done earlier in the year: the stock remains down 11 to 12 percent since January 1, and sits 21 percent below its 52-week high of €49.78, reached at the end of October.

A Quarter That Sent Two Different Signals

The buyback's supportive effect is colliding with a mixed earnings picture that emerged in late July, when Siemens Healthineers reported its fiscal third-quarter results. Revenue came in at €5.76 billion, up from €5.66 billion in the prior-year period — a gain of roughly 1.8 to 2.8 percent depending on the measure used. Net profit climbed 20 percent to €676 million, helped in part by refunds tied to US tariffs, while adjusted earnings per share rose to €0.70 from €0.49.

The headline numbers, however, mask a more complicated story. Management cut its full-year comparable revenue growth guidance to 3.5 to 4.0 percent, down from the 4.5 to 5.0 percent previously promised, citing weakness in the Diagnostics segment. At the same time, the company raised its adjusted EPS forecast to €2.35 to €2.45, up from €2.20 to €2.30. The net effect: Siemens Healthineers is earning more per euro of revenue but growing more slowly than originally planned, leaving investors to debate whether the margin improvement is structural or largely a function of one-off cost effects.

The mixed readout drew a measured response from Deutsche Bank, which on Tuesday nudged its price target from €38.00 to €39.00 while keeping a Hold rating. Analysts described the quarter as "mixed," pointing to revenue misses in Diagnostics and flagging caution over cost trends and the situation in the Middle East. UBS, for its part, reaffirmed a Neutral stance with a €38 target earlier in the month, noting that organic growth in the Imaging division — at 2.3 percent — came in well below the consensus estimate of 5.4 percent. That assessment dates from August 3 and should not be read as a current market consensus, but it underscores which division continues to dominate the debate around the company.

The Breakup Clock Keeps Ticking

While the buyback and quarterly numbers occupy the near-term narrative, the longer-term story revolves around the planned separation from parent Siemens AG. According to Dow Jones reporting, Siemens CFO Ralf Thomas confirmed in early August that outstanding tax questions with the financial authorities have been resolved, keeping the spin-off timeline intact. The plan, as previously reported by Handelsblatt and dpa, calls for Siemens shareholders to vote at the annual general meeting in February 2027 on a direct spin-off of 30 percent of the Healthineers stake. That would reduce Siemens' holding from its current 67 percent to below 40 percent, effectively turning Healthineers into a pure financial investment for the parent.

The combination of tax clarity and a steady buyback paints a picture of a company in transition: management signaling confidence in its own valuation through share repurchases, while the corporate structure prepares for a fundamental reshaping. For investors, the near-term question is whether the margin improvement can hold up against a lowered growth outlook — and whether the Imaging division's sluggishness is a temporary blip or a more persistent drag.

The next major milestone comes on November 5, when the company is expected to report fourth-quarter results. Until then, the buyback remains one of the few reliable catalysts, even as the market weighs the growth concerns against the promise of greater independence from Munich.